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ELL targets c-Myc for proteasomal degradation
and suppresses tumour growth
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Gang Ouyang1, Jiangang Zhou1 & Wuhan Xiao1,2
Increasing evidence supports that ELL (eleven–nineteen lysine-rich leukaemia) is a key
regulator of transcriptional elongation, but the physiological function of Ell in mammals
remains elusive. Here we show that ELL functions as an E3 ubiquitin ligase and targets c-Myc
for proteasomal degradation. In addition, we identify that UbcH8 serves as a
ubiquitin-conjugating enzyme in this pathway. Cysteine 595 of ELL is an active site of the
enzyme; its mutation to alanine (C595A) renders the protein unable to promote the
ubiquitination and degradation of c-Myc. ELL-mediated c-Myc degradation inhibits
c-Myc-dependent transcriptional activity and cell proliferation, and also suppresses
c-Myc-dependent xenograft tumour growth. In contrast, the ELL(C595A) mutant not only
loses the ability to inhibit cell proliferation and xenograft tumour growth, but also promotes
tumour metastasis. Thus, our work reveals a previously unrecognized function for ELL as an
E3 ubiquitin ligase for c-Myc and a potential tumour suppressor.
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T
he product of the eleven–nineteen lysine-rich leukaemia
(ELL) gene was ﬁrst identiﬁed as a translocation partner of
the mixed-lineage leukaemia (MLL) gene in acute myeloid
leukaemia (AML)1. Subsequent studies identiﬁed ELL as a
transcription elongation factor that could increase the rate of
transcriptional elongation by RNA polymerase II in vitro, and
later in vivo studies revealed its association with transcriptionally
active loci2,3. ELL is a part of two distinct elongation complexes,
the super elongation complex (SEC) and the little elongation
complex (LEC)4–6. The SEC plays several important functions,
such as HSP70 induction7,8, HOX gene dysregulation7 and HIV
transcription activation9,10. The LEC functions at the initiation
and elongation phases of snRNA gene transcription5,11.
In mammals, ELL is required for early embryogenesis12. Moreover,
ELL has been identiﬁed as a partner of steroid receptors, hypoxia-
inducible factor 1-alpha (HIF-1a), E2F1 and the TFIIH complex,
modulating their binding partner’s activity13–16.
The proto-oncogene, c-Myc, is frequently translocated in multiple
myeloma and is highly ampliﬁed or mutated in many different
human cancers17. The c-Myc gene encodes a multifunctional
transcription factor that plays important roles in regulating the
expression of genes contributed to tumorigenesis, tumour
maintenance as well as tumour metastasis17. One of the most
prominent mechanisms to degrade c-Myc is through the ubiquitin-
proteasome pathway18,19. Fbw7 is the best studied E3 ubiquitin ligase
for mediating c-Myc inhibition through degradation20,21. Another
RING-FINGER E3 ligase, Skp2, recognizes a conserved sequence
element in the amino terminus of c-Myc (MBII) and HLH-LZ motifs
(amino acids 367–439), promoting its poly-ubiquitination and
degradation22,23. The third RING-FINGER E3 ligase, b-TrCP,
binds to the amino terminus of c-Myc and uses the UbcH5
ubiquitin-conjugating enzyme (E2) to form heterotypic polyubiquitin
chains on c-Myc24. The only homologous to E6-AP C-terminus
(HECT) E3 ligase reported for c-Myc, HectH9, ubiquitinates c-Myc,
forming a lysine 63-linked polyubiquitin chain25, which does not
trigger c-Myc degradation but, instead, is required for the
transactivation of multiple target genes by c-Myc25.
As one of the classic oncogenes, c-Myc is overexpressed in
about 70% of human tumours; however, only 20% of these
tumours exhibit c-Myc gene ampliﬁcation or translocation18.
Thus, the deregulation of E3 ubiquitin ligase may contribute to
the overexpression of c-Myc observed in human tumours. In fact,
aberrant expression and/or mutation of some E3 ligases of c-Myc
have been reported in tumours18,26–28.
In this study, we reveal a previously unrecognized function for
ELL as an E3 ubiquitin ligase for c-Myc.
Results
ELL promotes c-Myc degradation. Using an anti-Myc antibody
(9E10, Santa Cruz) to detect Myc-tagged proteins in transfected
cells, we noticed that it could also detect a band of B67 kDa,
which was likely endogenous c-Myc. Intriguingly, the endogenous
c-Myc band disappeared with Myc-ELL overexpression. This
phenomenon led us to hypothesize that ELL might mediate
c-Myc degradation. Ectopic expression of HA-ELL reduced HA-
c-Myc protein levels (Fig. 1a). Because phosphorylation at Ser 62
stabilizes c-Myc, whereas subsequent phosphorylation at Thr 58
is required for c-Myc degradation29, we next examined whether
ELL promoted degradation of a c-Myc Thr 58 phosphorylation-
dead mutant, T58A, a Ser 62 constitutive-phosphorylation
mutant, S62E, as well as a Burkitt’s lymphoma-derived Myc
mutant, P57S. Overexpression of ELL induced degradation of all
the mutants as well as the wild-type c-Myc (Fig. 1a,b). These
results suggest that c-Myc phosphorylation is dispensable for
ELL-mediated degradation.
To further examine the effects of ELL on the stability of the
wild-type c-Myc, as well as that of the c-Myc mutants, we co-
transfected the wild-type or mutant c-Myc with HA-ELL or HA
empty vector control in the presence of cycloheximide
(50 mgml 1) and performed time-cause assays. Overexpression
of ELL accelerated degradation of the wild-type and mutant
c-Myc (Supplementary Fig. 1A–E). Furthermore, overexpression
of ELL in HCT116 cells induced endogenous c-Myc degradation
in a dose-dependent manner (Fig. 1c). In contrast, knockdown of
ELL in HCT116 cells enhanced endogenous c-Myc stability
(Fig. 1d) even in the presence of 50mgml–1 cycloheximide
(Supplementary Fig. 1F).
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Figure 1 | ELL induces c-Myc degradation. (a) Co-transfection of ELL induces the protein degradation of wild-type c-Myc as well as the T58A and P57S
mutants in HEK293 cells. (b) Co-transfection of ELL induces the protein degradation of the c-Myc S62E mutant. (c) Overexpression of ELL in HCT116 cells
reduces endogenous c-Myc protein degradation in a dose-dependent manner. (d) shRNA-mediated ELL knockdown in HCT116 cells by ELL-shRNAs
(ELL-shRNA-1 and ELL-shRNA-2) enhances endogenous c-Myc protein level.
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To determine whether ELL can affect the transcription of
c-Myc, we overexpressed or knocked down of ELL in HCT116
cells and examined the mRNA levels of c-Myc. Neither
overexpression of ELL nor knockdown of ELL had obvious effect
on c-Myc mRNA levels (Supplementary Fig. 2A and B).
Taken together, these results suggest that ELL induces c-Myc
protein degradation in a manner that is not dependent on c-Myc
phosphorylation and new protein synthesis.
ELL interacts with c-Myc in vivo and in vitro. To gain insight
into the mechanisms by which ELL induces c-Myc degradation,
we examined whether ELL interacts with c-Myc. RFP-tagged
c-Myc co-localized with GFP-tagged ELL in the nucleus of Cos7,
HEK293T and HCT116 cells, forming nuclear speckles (Fig. 2a;
Supplementary Fig. 3A). To examine whether RFP-c-Myc co-
localized with GFP-ELL in the nucleolus, we co-transfected RFP-
c-Myc with GFP-tagged BM5, a nucleolus marker30, into Cos7
cells with or without ectopic expression of ELL. Notably, the
speckles formed by GFP-BM5 were clearly separated from the
speckles formed by co-localization of RFP-c-Myc and HA-ELL
(Supplementary Fig. 3B), thus ruling out the possibility that ELL
co-localized with c-Myc in the nucleolus. Next, we examined
whether ELL co-localize with Max or Mxd. In the presence of
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Figure 2 | ELL interacts with c-Myc. (a) RFP-tagged c-Myc co-localizes with GFP-tagged ELL in the nucleus after co-transfection into Cos7 cells. The
nucleus were stained by Hoechst 33342. (b) Co-immunoprecipitation of human c-Myc with human HA-ELL in HEK293Tcells transfected with the indicated
plasmids. (c) Co-immunoprecipitation of human Flag-ELL with human HA-c-Myc in HEK293T cells transfected with the indicated plasmids. (d) Co-
immunoprecipitation of endogenous ELL with endogenous c-Myc in HCT116 cells. (e) ELL directly interacts with c-Myc. (f) Schematic of the ELL domains.
The extent of the interaction between c-Myc and the ELL domains is indicated by the number of plus signs. (g–i) Co-immunoprecipitation of human HA-c-
Myc with Myc-tagged ELL domains in HEK293Tcells transfected with the indicated plasmids. (j) Schematic of c-Myc domains. The extent of the interaction
between ELL and the c-Myc domains is indicated by the number of plus signs. (k–n) Co-immunoprecipitation of human Flag-ELL and HA-tagged c-Myc
domain in HEK293T cells transfected with the indicated plasmids. IB, immunoblotting; TCL, total cellular lysates.
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HA-c-Myc, GFP-ELL co-localized with RFP-Max (Supplementary
Fig. 3C). However, in the absence or presence of c-Myc, GFP-ELL
did not co-localize with RFP-Mxd (Supplementary Fig. 3D).
Co-immunoprecipitation assays showed that Myc-tagged
c-Myc could pull down HA-ELL after co-transfection into
HEK293 cells (Fig. 2b). Similarly, Flag-ELL could also pull down
HA-c-Myc (Fig. 2c). Co-immunoprecipitation assays in HCT116
cells using a polyclonal anti-c-Myc antibody (A0309, ABclonal)
indicated that c-Myc interacted with endogenous ELL (Fig. 2d).
Moreover, glutathione S-transferase (GST)-pull-down assays
using GST-tagged c-Myc and His-tagged ELL expressed in
Escherichia coli (E. coli) showed that GST-tagged c-Myc could
pull down His-tagged ELL (Fig. 2e). These results suggest that
endogenous ELL directly interacts with c-Myc.
We subsequently mapped the domains of ELL and c-Myc that
are responsible for their interaction (Fig. 2f,j). The C terminus of
ELL (amino acids (aa) 466–621) was crucial for interaction with
c-Myc (Fig. 2g–i), and the N terminus (aa 1–144) and C terminus
(aa 368–439) of c-Myc were required for interaction with ELL
(Fig. 2k–n). Notably, the DNA-binding domain of c-Myc (aa
143–355) did not interact with ELL (Fig. 2m), but the mutant
with Max-binding domain (aa 1–354) deletion could still bind to
ELL.
ELL is an E3 ubiquitin ligase. To characterize the type of protein
degradation mediated by ELL, we took advantage of inhibitors,
including chloroquine (lysosomal proteolysis inhibitor), NH4Cl
(lysosomal proteolysis inhibitor), AICAR (macro-autophagy
inhibitor) and MG132 (proteasome inhibitor). Only the protea-
some inhibitor, MG132, could block ELL-mediated c-Myc
degradation (Fig. 3a–c), suggesting that ELL promotes c-Myc
degradation via the proteasome pathway. To validate that ELL
indeed participates in the proteasomal degradation of c-Myc, we
performed in vivo ubiquitination assays by co-transfecting His-
ubiquitin and HA-c-Myc into HEK293T cells together with a Myc
empty vector or Myc-ELL. Overexpression of ELL enhanced the
poly-ubiquitination of c-Myc (Fig. 3d). Given the role of lysine
(K) 48-linked poly-ubiquitination in proteolysis19, we performed
an ubiquitination assay using an ubiquitin mutant, Ub(K48R),
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Figure 3 | ELL mediates c-Myc proteasomal degradation. (a) The lysosomal inhibitor, chloroquine diphosphate (Chlq, 10mM), and the autophagy
inhibitor, AICAR (0.2mM), do not block ELL-induced Flag-c-Myc degradation. (b) The lysosomal inhibitor, NH4Cl (25mM), does not block ELL-induced
HA-c-Myc degradation. (c) ELL-induced degradation of HA-c-Myc was blocked by the proteasome inhibitor, MG132 (20mM). (d) ELL enhances the poly-
ubiquitination of c-Myc. (e) ELL does not enhance the poly-ubiquitination of c-Myc when ubiquitin K48 is mutated to R (K48R). (f) Alignment of partial ELL
sequences (583–614 amino acids in human ELL) from human, mouse, rat and zebraﬁsh. The cysteine at position 595 (C595) of human ELL was mutated to
alanine (C595A). (g) The ELL(C595A) mutant does not induce c-Myc degradation. (h) Overexpression of the ELL(C595A) mutant does not obviously alter
endogenous c-Myc protein level. (i) The ELL(C595A) mutant does not enhance the poly-ubiquitination of c-Myc. NS, non-speciﬁc band.
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which cannot form K48-conjugated polyubiquitin chains. ELL
strongly induced the poly-ubiquitination of c-Myc in the presence
of wild-type ubiquitin, but not K48R ubiquitin (Fig. 3e),
suggesting that ELL promotes the formation of K48-linked
polyubiquitin chains on c-Myc.
These data led us to further hypothesize that ELL might have
E3 ubiquitin ligase activity. We performed domain mapping of
ELL and analysed c-Myc degradation, we found that aa 583–614
of ELL is required for ELL-mediated c-Myc degradation (Fig. 2g;
Supplementary Fig. 4). Within this region, there is only one
cysteine (C) located at position 595 (C595), which is evolutio-
narily conserved from zebraﬁsh to human (Fig. 3f). Because the
HECT and RBR-domain E3 ligases have a cysteine active site
required for their catalytic activity19, we examined whether ELL
still functions as an E3 ligase if C595 of ELL is mutated to alanine
(C595A). The ELL(C595A) mutant did not promote c-Myc
degradation even though it could still interact with c-Myc
(Fig. 3g; Supplementary Fig. 5). Moreover, compared with wild-
type ELL, overexpression of the ELL(C595A) mutant had no
obvious effect on the stability of endogenous c-Myc (Fig. 3h). In
contrast to that of wild-type ELL, overexpression of the
ELL(C595A) mutant diminished the poly-ubiquitination of
c-Myc (Fig. 3i). These results suggest that ELL might have E3
ubiquitin ligase activity and that cysteine 595 is an active site.
To evaluate whether ELL is a bona ﬁde E3 ubiquitin ligase, we
conducted in vitro ubiquitination assays using an ubiquitinylation
kit (UW9920, BioMol). To deﬁne which E2 enzymes are involved
in ELL mediating c-Myc proteasomal degradation, we ﬁrst cloned
11 E2 enzymes indicated in the kit into CMV-Myc expression
vector and examined their binding ability to ELL. Three E2
enzymes including UbcH8, UbcH6 and UbcH5b could bind to
ELL, and UbcH8 has the strongest binding ability, UbcH5b has
the weakest binding ability, but other eight E3 enzymes do not
bind to ELL at all (Fig. 4a,b). Subsequently, we expressed His6-
ELL, His6-ELL(C595A) and His6-c-Myc in E. coli and puriﬁed
them by afﬁnity puriﬁcation (Supplementary Fig. 6A and B).
Then, we performed ubiquitination assays according to the
protocol provided by the kit (UW9920, BioMol) with some
modiﬁcations. Only adding of UbcH8 in the reaction caused
dramatic poly-ubiquitination of His6-c-Myc in the presence of
His6-ELL, and adding of UbcH5b caused poly-ubiquitination of
His6-c-Myc at very low level, but adding of other E2 enzymes did
not cause obvious poly-ubiquitination of His6-c-Myc (Fig. 4c).
Moreover, compared with adding His6-ELL to the reaction,
adding of His6-ELL(C595A) did not induce poly-ubiquitination
of His6-c-Myc in the presence of UbcH8 (Fig. 4d). These data not
only suggest that ELL itself has E3 ligase activity, but also indicate
that UbcH8 serves as an E2 ubiquitin-conjugating enzyme in the
pathway. In addition, the ELL(C595A) mutant loses E3 ubiquitin
ligase activity.
As a typical E3 ubiquitin ligase usually catalyses its targets at
lysine (K) residue(s) to form polyubiquitin chains19, we next
determined which lysine residues in c-Myc are catalysed by ELL.
Given that ELL promotes wild-type c-Myc degradation, we used
the protein degradation efﬁciency by ELL to monitor the potential
ubiquitination site(s) in c-Myc. Overexpression of ELL did not
promote degradation of the K51/52R, K397R and K430R mutants
(Fig. 5a–c; Supplementary Fig. 7A and B). Compared with that of
the wild-type c-Myc, ELL-induced poly-ubiquitination of the
K51/52R, K397R and K430R mutants, as well as that of the
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Figure 4 | ELL function as an E3 ubiquitin ligase. (a,b) Co-immunoprecipitation assays between ELL and 11 E2 ubiquitin-conjugating enzymes show that
UbcH8 has the strongest binding ability to ELL, UbcH6 and UbcH5b have weaker binding ability to ELL; other E2 enzymes do not interact with ELL. (c) In
vitro ubiquitination assays show that in the presence of UbcH8 (E2), the puriﬁed ELL expressed in E. coli induces poly-ubiquitination of puriﬁed c-Myc
expressed in E. coli most efﬁciently; and in the presence of UbcH5b (E2), ELL induces poly-ubiquitination of c-Myc mildly. (d) In vitro ubiquitination assays
show that the puriﬁed ELL expressed in E. coli induces poly-ubiquitination of puriﬁed c-Myc expressed in E. coli even in the presence of UbcH8 (E2) and ATP,
but ELL(C595A) does not. Ubc1 (E1) and biotinylated ubiquitin were added to all of the reactions. ub, ubiquitin.
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four-site mutant 4K/R (K51/52/397/430R), was reduced
(Fig. 5d,e). However, all the mutants could still interact with
ELL (Supplementary Fig. 7C). These data suggest the K51/52,
K397 and K430 in c-Myc are key sites for c-Myc poly-
ubiquitination catalysed by ELL. In addition, it appears that
simultaneous ubiquitination of these key sites by ELL is required
for c-Myc degradation because two single-site mutants (K397R,
K430R) and one double-site mutant (K51/52R) were not
degraded by ELL efﬁciently (Fig. 5a–c).
Collectively, these results suggest that ELL is a bona ﬁde E3
ubiquitin ligase, targeting c-Myc for proteasomal degradation, and
that UbcH8 serves as an E2 ubiquitin-conjugated enzyme in this
pathway. In addition, cysteine 595 in ELL serves as an active site.
ELL inhibits c-Myc transcriptional activity. To evaluate the
biological consequences of ELL-mediated c-Myc degradation, we
examined the effect of ELL on c-Myc-dependent transactivation.
Using a mammalian one-hybridization system by co-transfecting
HA-ELL together with c-Myc fused to the GAL4 DNA-binding
domain, overexpression of ELL signiﬁcantly inhibited the transcrip-
tional activity of c-Myc (Supplementary Fig. 8A). Next, we examined
the effect of ELL on the transactivation of two well-deﬁned c-Myc
target genes, hTERT31 and E2F2 (ref. 32). c-Myc activated the hTERT
promoter by B2.8-fold. But, co-expression of ELL together with
c-Myc decreased hTERT promoter activity (Fig. 6a). In contrast, co-
expression of the ELL(C595A) mutant together with c-Myc had no
obvious effect on c-Myc transcriptional activity (Fig. 6a). Similar
results were obtained for E2F2 promoter activity (Fig. 6b) with the
exception that co-expression of ELL(C595A) with c-Myc suppressed
E2F2 promoter activity (Fig. 6b).
Subsequently, we used semi-quantitative reverse transcription
(RT)-PCR to examine the effect of ELL on c-Myc-dependent
transactivation. c-Myc induced hTERT mRNA levels B2.8-fold
(Fig. 6c), which was reduced with co-expression of ELL, but not
ELL(C595A) (Fig. 6c). Similar results were obtained for ELL on
E2F2 mRNA level (Fig. 6d). In agreement with the promoter
assays, co-expression of the ELL(C595A) mutant with c-Myc
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Figure 6 | ELL inhibits c-Myc transcriptional activity. (a) Overexpression of ELL suppresses hTERT promoter reporter activity induced by c-Myc
(Po0.0001, t-test), but overexpression of ELL(C595A) does not (P¼0.0779, t-test). (b) Overexpression of ELL and ELL(C595A) suppresses E2F2
promoter reporter activity induced by c-Myc (Po0.0001 and P¼0.0017, respectively, t-test). (c) Overexpression of ELL inhibits the expression of hTERT
activated by c-Myc (Po0.0001, t-test), but overexpression of ELL(C595A) does not (P¼0.6769, t-test). (d) Overexpression of ELL and ELL(C595A)
inhibits the expression of E2F2 activated by c-Myc (P¼0.0023 and P¼0.0011, respectively, t-test). (e) The expression of HA-ELL, HA-ELL(C595A) and
HA-c-Myc in HEK293T cells is conﬁrmed. (f,g) Knockdown of ELL in HEK293T cells by pSuper-ELL-shRNA1 and pSuper-ELL-shRNA2 enhances hTERT
(f) and E2F2 (g) promoter reporter activity. (h,i) Knockdown of ELL in HEK293Tcells by pSuper-ELL-shRNA1 increases hTERT (h) and E2F2 (i) mRNA levels.
(j) pSuper-ELL-shRNA1- and pSuper-ELL-shRNA2-mediated knockdown of ELL is conﬁrmed. (k) Overexpression of ELL inhibits hTERT expression
(Po0.0001, t-test), but overexpression of ELL(C595A) does not (P¼0.0593, t-test). (l) Overexpression of ELL and ELL(C595A) inhibits E2F2
expression(Po0.0001 and P¼0.0006, respectively, t-test). (m) The expression of HA-ELL and HA-ELL(C595A) in HEK293Tcells is conﬁrmed by western
blot analysis. (n) Overexpression of ELL in HCT116 cells reduces c-Myc binding to hTERT promoter (Po0.0001, t-test). (o) Overexpression of ELL in
HCT116 cells reduces c-Myc binding to E2F2 promoter (Po0.0001, t-test). (p) Knockdown of ELL in HCT116 cells by pSuper-ELL-shRNA-1 enhances c-Myc
binding to hTERT promoter (P¼0.0025, t-test). (q) Knockdown of ELL in HCT116 cells by pSuper-ELL-shRNA-1 enhances c-Myc binding to E2F2 promoter
(P¼0.0025, t-test). (r) Overexpression of HA-MLL-ELL does not induce Flag-c-Myc degradation. (s) Overexpression of HA-MLL-ELL does not promote
c-Myc poly-ubiquitination. (t,u) Overexpression of HA-MLL-ELL has no inhibitory effect on hTERT (t) or E2F2 (u) promoter reporter activity induced by
c-Myc. Data are presented as mean ±s.e.m. of three independent experiments performed in triplicate.
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suppressed E2F2 expression (Fig. 6d). The expression of
transfected HA-c-Myc, HA-ELL and HA-ELL(C595A) was
conﬁrmed (Fig. 6e).
To further explore the inﬂuence of ELL on c-Myc-dependent
transactivation, we analysed the effect of ELL knockdown by
transfection with two ELL-shRNA constructs, pSuper-ELL-shRNA-1
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Figure 7 | ELL inhibits cell proliferation. (a) Overexpression of ELL via lentivirus infection signiﬁcantly inhibits HCT116 cell proliferation. (b) Lentivirus-
mediated overexpression of ELL signiﬁcantly inhibits the colony formation of HCT116 cells (P¼0.0011, t-test). (c) Expression of ELL in HCT116 cells is
conﬁrmed by western blot analysis. (d) Overexpression of the ELL(C595A) mutant via lentivirus infection has no obvious effect on HCT116 cell
proliferation. (e) Overexpression of the ELL(C595A) mutant via lenti-virus infection has no obvious effect on the colony formation of HCT116 cells
(P¼0.2250, t-test). (f) Expression of the ELL(C595A) mutant in HCT116 cells is conﬁrmed by western blot analysis. (g,h) ELL-shRNA-mediated
knockdown of ELL enhances HCT116 cell proliferation (g) and colony formation (P¼0.0354, t-test) (h). (i) Knockdown of ELL in HCT116 cells is conﬁrmed
by western blot analysis. (j) Overexpression of ELL in Rat1 cells (wild-type c-Myc) via lentivirus infection signiﬁcantly inhibits cell proliferation.
(k) Overexpression of ELL in HO15.19 cells (c-Myc-null) via lentivirus infection has no obvious effect on cell proliferation. Data are presented as mean
±s.e.m. of three independent experiments performed in triplicate.
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and pSuper-ELL-shRNA-2 (ref. 15). Knockdown of ELL by two
ELL-shRNA constructs in HEK293T cells caused an increase in
hTERT and E2F2 promoter activity (Fig. 6f,g), and hTERT and E2F2
mRNA levels (Fig. 6h,i). Knockdown of ELL by ELL-shRNAs was
conﬁrmed (Fig. 6j).
To determine the effect of overexpression of ELL on
endogenous c-Myc activity, we examined expressions of hTERT
and E2F2 with overexpression of ELL or ELL(C595A) via
transient transfection. Overexpression of ELL reduced hTERT
mRNA level, but overexpression of ELL(C595A) did not (Fig. 6k).
Overexpression of both ELL and ELL(C595A) reduced E2F2
mRNA level (Fig. 6l). Overexpression of ELL and ELL(C595A)
was conﬁrmed (Fig. 6m).
To determine whether transcription regulation by c-Myc
is affected by ELL, we performed chromatin immuno-
precipitation assays (ChIP). Overexpression of ELL reduced
c-Myc binding to the promoters of hTERT and E2F2 dramatically
(Fig. 6n,o). However, knockdown of ELL by pSuper-ELL-shRNA-
1 enhanced c-Myc binding to the promoters of hTERT and E2F2
(Fig. 6p,q).
To determine the physiological relevance of ELL-mediated
c-Myc degradation, we examined the effect of the MLL-ELL
fusion protein, an oncogenic protein identiﬁed in AML1, on
c-Myc function. Co-expression of MLL-ELL together with c-Myc
in HEK293T cells had no obvious effect on c-Myc stability as
compared with co-expression with ELL (Fig. 6r). In addition, co-
expression of MLL-ELL did not enhance the poly-ubiquitination
of c-Myc (Fig. 6s) or hTERT and E2F2 promoter activity
(Fig. 6t,u).
We next determined whether the ELL-mediated inhibition
of hTERT and E2F2 promoter activity and mRNA expression
was dependent on c-Myc. We generated three stable HCT116
cell lines with lentiviruses. The ﬁrst cell line expressed c-Myc-
shRNA, which targets the 50 untranslated region region of
c-Myc (Supplementary Fig. 8B). The second and third cell lines
were established by re-infecting the ﬁrst cell line with lentiviruses
expressing the wild-type c-Myc or the c-Myc(4K/R) mutant
(Supplementary Fig. 8C). In cells with stable c-Myc-knock down,
overexpression of ELL had no inhibitory effect on hTERT and
E2F2 promoter activity (Supplementary Fig. 8D and E) or mRNA
levels (Supplementary Fig. 8F and 8G). On c-Myc restoration,
the inhibitory effects of ELL on the activation of hTERT and
E2F2 promoter was restored (Supplementary Fig. 8H–K).
Notably, similar to that exhibited above (Fig. 6b,d,l),
overexpression of the ELL(C595A) mutant still suppressed E2F2
expression in HCT116 cells with c-Myc restoration
(Supplementary Fig. 8I and K), further conﬁrming the inhibitory
role of ELL(C595A) on E2F2. The expression of HA-ELL
and HA-ELL(C595A) was conﬁrmed (Supplementary Fig. 8L).
Moreover, in HCT116 cells with c-Myc(4K/R) ectopic expres-
sion, the inhibitory effects of ELL on expression of hTERT and
E2F2 were not detected by both promoter assays and semi-
quantitative RT–PCR assays (Supplementary Fig. 8M–P). The
expression of HA-ELL and HA-ELL(C595A) was conﬁrmed
(Supplementary Fig. 8Q).
Taken together, these results suggest that ELL inhibits c-Myc-
dependent transcriptional activity. In addition, although the
enzymatic dead mutant, ELL(C595A), is unable to inhibit the
expression of one of c-Myc target, hTERT, it retains the ability to
inhibit the expression of another c-Myc target, E2F2, suggesting
that ELL rather than acting as an E3 ubiquitin ligase might
differentially inhibit c-Myc transcriptional activity.
Of note, ELL(C595A) had no obvious effect on the interaction
between c-Myc and Max (Supplementary Fig. 9). In addition, ELL
could not affect the suppressive function of c-Myc on Gadd45a
expression (Supplementary Fig. 10).
ELL suppresses cell growth and proliferation. ELL has been
shown to induce apoptosis33. However, we did not observe a
relative higher apoptotic ratio in HCT116 cells with lentivirus-
mediated ELL overexpression compared with the control cells
(Supplementary Fig. 11A and B). So, stable overexpression of ELL
might not induce cell apoptosis.
To further demonstrate the biological function of ELL in
mediating c-Myc degradation and inhibiting its transcriptional
activity, we examined its effect on cell proliferation using three
stable HCT116 cell lines generated by lentivirus infection, control,
ELL and ELL(C595A). Compared with the control cells, HCT116
cells with ELL overexpression proliferated much slower from day
2 (Fig. 7a), which was further validated by colony formation
assays (Fig. 7b). The expression of ELL in HCT116 cells was
conﬁrmed (Fig. 7c). In contrast, the proliferation rate of the
HCT116 cells with stable ELL(C595A) mutant expression is
similar to that of control cells (Fig. 7d), which was also conﬁrmed
by colony formation assays (Fig. 7e). The expression of
ELL(C595A) was conﬁrmed (Fig. 7f). Conversely, the HCT116
cells with stable ELL knockdown proliferated faster as compared
with that of control cells expressing scrambled shRNA (Fig. 7g,h).
The efﬁciency of ELL-shRNA-mediated knockdown was con-
ﬁrmed (Fig. 7i).
To further determine whether the effect of ELL on cell
proliferation is dependent on c-Myc, we took advantage of Rat1
and HO15.19 cells. Rat1 cells contain wild-type c-Myc, but
HO15.19 cells are derived from Rat1 with targeted disruptions of
both c-Myc gene copies22,34–37. Overexpression of ELL via
lentivirus infection suppressed Rat1 cell proliferation signiﬁcantly
(Fig. 7j). In contrast, overexpression of ELL had no obvious effect
on HO15.19 cell proliferation (Fig. 7k).
Taken together, these data suggest that ELL can inhibit cell
proliferation, which was mediated by c-Myc.
ELL suppresses xenograft tumour growth. To obtain more
insight into the role of ELL in cancer development, we performed
xenograft tumour growth assays using three stable HCT116 cell
lines described above. After the cells were subcutaneously injected
into 3–4-week-old male nude mice (n¼ 5 per group), tumour size
was measured every week from week 3. The growth rate of
HCT116 cell tumours overexpressing the ELL(C595A) mutant
was almost the same as that of the control; only one tiny tumour
formed after inoculation of HCT116 cells that overexpressed ELL
after week 5 (Fig. 8a,b). In addition, no obvious difference in
tumour weight between the control and ELL(C595A) tumours
(Fig. 8c). Tumour expression of ELL and ELL(C595A) was con-
ﬁrmed (Fig. 8d). These data suggest that ELL inhibits colon
cancer xenograft tumour growth.
Cachexia was observed in one mouse with an ELL(C595A)-
expressing tumour that died at week 4. In addition, at week 6
when the tumours were harvested, we found that two mice with
ELL(C595A)-expressing tumours also exhibited cachexia
(Supplementary Fig. 12A, red arrows), but we did not ﬁnd
cachexia symptom in the control mice with similar tumour
burden. Because cachexia is one of the common symptoms
exhibited in advanced cancer patients38, we analysed the tumours
of these two mice in detail. The tumours attached much tighter to
the ribs. In addition, macro-metastasis to the lung in these two
mice was conﬁrmed by histological analysis (Supplementary
Fig. 12B–D). These data suggest that the ELL(C595A) mutant not
only loses the tumour suppressive function, but also gains a
function for promoting tumour metastasis.
To further conﬁrm the above observations, we repeated
xenograft tumour growth assays. Due to no obvious tumours
were formed in mice with injections of ELL-overexpressing
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HCT116 cells, we excluded this cell line but added HCT116
parental cells as another control. No signiﬁcant difference in the
size and the growth rate of xenograft tumours was observed
among these three groups: parental cells, pHAGE control and
ELL(C595A)-overexpressing cells (Supplementary Fig. 13A and
B). Similar to the above observation (Supplementary Fig. 12A),
cachexia exhibited in two mice with injections of ELL(C595A)-
overexpressing HCT116 cells (Supplementary Fig. 13A, red
arrows). Particularly, one of the mice (Supplementary Fig. 13A,
yellow arrows) not only developed macro-metastasis in the whole
chest (Supplementary Fig. 13C), but also exhibited potential bone
invasion (Supplementary Fig. 13D). In addition, the other three
mice developed micro-metastasis in lung (Supplementary
Fig. 13E and F). These data further conﬁrm gain of function of
ELL(C595A) mutant in promoting metastasis.
To ﬁgure out the mechanisms regarding why the ELL(C595A)
mutant promotes tumour metastasis, initially, we performed cell
invasion assays. Overexpression of ELL(C595A) could enhance
invasive ability of cells (Supplementary Fig. 14). Therefore,
ELL(C595A) mutation might cause the cells to gain more invasive
capability but not of proliferation rate. Subsequently, we conducted
quantitative analysis of global proteome in six xenograft tumours
(three pHAGE control tumours versus three pHAGE-ELL(C595A)
tumours) (Supplementary Fig. 15A). After the assays by comparing 3
pHAGE-ELL(C595A) tumours with 3 pHAGE control tumours, 11
proteins were identiﬁed to be upregulated in pHAGE-ELL(C595A)
tumours (up-ratio41.2, Po0.05) (Supplementary Fig. 15B). To
conﬁrm these upregulations, we initially performed semi-quantitative
RT–PCR assays (Supplementary Table 2). The upregulations of
S100A4, MARCKSL1, BCAM, BAG4, IPO4 and CPSF7 in pHAGE-
ELL(C595A) tumours were conﬁrmed (Supplementary Fig. 15C).
Then, using a commercially available antibody, anti-S100A4, we
validated upregulation of S100A4 in pHAGE-ELL(C595A) tumours
(Supplementary Fig. 15D). S100A4, MARCKSL1 and BAG4 have
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Figure 8 | ELL suppresses colon tumour xenograft growth. (a) Overexpression of ELL inhibits HCT116 tumour xenograft growth in nude mice (n¼ 5), but
overexpression of the ELL(C595A) mutant has no obvious effect (n¼ 5 or n¼4, after week 4). Data are presented as mean ±s.e.m. (b) Tumours
harvested from the nude mice after 6 weeks. (c) The weight of the tumours after 6 weeks. control, n¼ 5; ELL(C595A), n¼4 (one mouse died at week 4);
ELL, n¼ 1 (no tumour grew in other four mice). Data are presented as mean ±s.e.m. (d) Expression of ELL, ELL(C595A) and c-Myc in the tumours is
conﬁrmed by western blot analysis. (e) Representative pictures of normal colon tissues and colon cancer specimens stained with an anti-ELL antibody
(upper panel) or anti-c-Myc antibody (lower panel). (f,g) Expression of c-Myc (f) and ELL (g) in human colon cancer specimens (n¼90) and normal colon
tissues (n¼86) as revealed by immunohistochemistry using an anti-c-Myc and anti-ELL antibodies, respectively.
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been reported to play important roles in promoting tumour
metastasis39–48. Thus, ELL(C595A) mutant might promote tumour
metastasis through inducing these metastasis-associated genes.
We further performed immunohistochemistry (IHC) analysis
of human colon cancer arrays. ELL and c-Myc were mainly
detected in the nucleus of epithelial cells (Fig. 8e). The frequency
of c-Myc-positive nuclear staining increased in colon cancer
specimens compared with that in the non-tumour containing
tissues (72.2% versus 41.86%, respectively; Fig. 8f)49. In contrast,
the frequency of ELL-positive staining decreased in colon cancer
specimens compared with the non-tumour containing tissues
(37.7% versus 65.12%, respectively; Fig. 8g). These data suggest
that ELL is downregulated in colon cancer, which is negatively
correlated with the elevated expression of c-Myc.
Based on the observations, we propose a working model of
ELL-mediated c-Myc degradation (Supplementary Fig. 16).
Discussion
A series of studies revealed that ELL plays important roles in
transcription control, particularly as a component of both SEC and
LEC4,6. Nonetheless, in mammals, the in vivo physiological function
of ELL has remained poorly understood in mechanistic terms due to
the early embryonic lethality of ELL-null mice12. In this study, we
conﬁrmed the ubiquitin ligase activity of ELL. However, no obvious
conserved structural domains of typical E3 ligases, such as a RING-
FINGER or a HECT domain19, have been identiﬁed in ELL.
Moreover, it appears that ELL cannot be attributed to any of the
components in the multiple RING-type E3 complexes19. Therefore,
ELL might represent a novel type of E3 ubiquitin ligase. Given that
ELL(C595A) mutant is inactive for catalysing poly-ubiquitination, it
appears that ELL has characteristics similar to that of HECT and
RBR-domain E3 ligases, in which an active cysteine is required for
accepting ubiquitin from the E2 and then transferring it from the E3
to the substrate19.
Regarding that plenty of studies strongly support a crucial role
for ELL in the control of transcriptional elongation, it is possible
that these effects may be mediated through targeting other
components of either the SEC or LEC complex for proteasomal
degradation. In fact, some E3 ligases regulate transcription
elongation through targeting their substrates50–52. Thus, no
irreconcilable contradictions exist between the identiﬁcation of
ELL as an E3 ligase and its recognized role as a key regulator of
transcriptional elongation. Moreover, because c-Myc has also
been shown to regulate transcription elongation53, ELL may
regulate transcription elongation through modulating c-Myc.
E3 ligase usually has multiple targets. Thus, ELL might also
have other targets in addition to c-Myc. Recent work showed that
ELL interacts with the THIIF complex and that helps the RNA
polymerase II to restart the transcription after DNA repair16. ELL
E3 ubiquitin ligase activity can nicely explain this function of
ELL16. In addition, ELL was also previously puriﬁed as a
component in combined nuclear and cytoplasmic lysates that
were bound to ELL-associate proteins (EAP), including EAP45,
EAF30 and EAF20 (ref. 54). These proteins were later found to be
identical to Vps 36, Vps 22 and Vps 25 of the endosomal sorting
complex required for transport system (ESCRTII)55. The ESCRT
system is linked to degradation of growth factor receptors like
epidermal growth factor receptor (EGFR)56. Therefore, ELL E3
ligase might also involve in transcription regulation by targeting
membrane bound growth factor receptors for degradation
through the ESCRT II pathways.
Of note, the oncogenic fusion protein, MLL-ELL, which
contains aa 46–621 of ELL1, loses the ability to promote c-Myc
poly-ubiquitination and degradation. This phenomenon might be
a result of a conformation change in ELL after its fusion with
MLL13,15. To date, the mechanism by which MLL-ELL induces
AML remains poorly understood57. It is possible that loss of the
ability to induce c-Myc degradation might underlie MLL-ELL-
related leukaemogenesis. In the future, it is worth to collect the
AML samples with MLL-ELL translocation and check them to see
whether c-Myc protein in these samples is stabilized.
It seems that the protein level of c-Myc protein varied among
ELL(C595A) mutant xenograft tumours (Fig. 8d; Supplementary
Fig. 13A). Based on protein degradation and ubiquitination assays
in vitro and in vivo, ELL(C595A) mutant lost its E3 ligase activity.
So, it was supposed not to affect c-Myc protein level. However,
regarding that ELL(C595A) mutant could still bind to ELL and
suppress E2F2 expression, ELL(C595A) mutant might still
regulate the activity or the stability of c-Myc through an
yet-unknown mechanism other than acting E3 ligase activity.
Factors that modulate c-Myc activity might contribute to
tumour initiation and progression18. Fbw7 is a well-deﬁned
tumour suppressor as it downregulates c-Myc activity18. In
contrast, Skp2 and HectH9 are considered oncogenes because they
positively regulate c-Myc transcriptional activity18. In this study,
we found that ELL suppresses the expression of hTERT and E2F2,
two well-deﬁned c-Myc down-stream target genes, by targeting
c-Myc degradation. However, MLL-ELL was unable to suppress
hTERT and E2F2 expression. Furthermore, overexpression of ELL
in HCT116 colon cancer cells inhibited cell proliferation and
xenograft tumour growth in nude mice. In addition, ELL
expression was decreased in human colon cancer specimens
compared with normal tissues, and was negatively correlated with
c-Myc expression. These observations suggest that ELL might
contribute to tumour suppression.
In this study, we provided evidences to show that suppression
of hTERT and E2F2 expression by ELL is dependent on c-Myc
(Supplementary Fig. 8). In addition, it appears that the inhibitory
role of ELL on cell proliferation is also mediated by c-Myc
regarding the facts that overexpression of ELL inhibited Rat1 cell
(wild-type c-Myc) proliferation, but did not inhibit HO15.19 cell
(c-Myc deﬁcient) proliferation, and that overexpression/knock-
down of ELL in HCT116 cells inhibited or enhanced cell
proliferation with a good correlation of endogenous c-Myc level
(Fig. 7). Given that overexpression of ELL inhibited xenograft
tumour growth and ELL expression was negatively correlated
with c-Myc expression in human colon cancer specimens, the
suppressive role of ELL on tumour growth might also be
mediated by c-Myc. However, in this study, we could not
provide direct evidence to support this statement (Fig. 8). In
fact, we have tried to get direct evidence to conﬁrm the
c-Myc-dependent tumour suppressive role of ELL through
establishing stable cell lines using three-round lentivirus
infections based on the established stable cell lines with
endogenous c-Myc knockdown plus overexpression of wild-type
c-Myc (c-Myc-shRNA resistant) or c-Myc(4K/R) mutant. Unfor-
tunately, when these cell lines went through the third-round
infection with the lentiviruses expressing ELL or ELL(C595A)
mutant as well as ELL-shRNA, the cells became very unhealthy
(the most of cells were broken) for unknown reasons. In the
future, to avoid three-round lentivirus infections, other
approaches, such as CRISPR/Cas9, could be employed to
knockout of endogenous c-Myc at ﬁrst and then re-express
wild-type c-Myc or c-Myc(4K/R) mutant plus ELL or
ELL(C595A) mutant as well as ELL-shRNA for establishing
stable cell lines. The xenograft tumour growth assays based on
these cell lines might help to resolve this puzzle eventually.
Clearly, we still cannot rule out that additional ELL substrates,
except for c-Myc, play roles in mediating ELL’s function in
tumour suppression. Further studies are required to address the
identity and function of such substrates.
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Although the enzymatic inactivated mutant, ELL(C595A), lost
its ability to suppress hTERT expression, it did inhibit E2F2
expression. ELL(C595A) also lost its ability to inhibit cancer cell
proliferation and xenograft tumour growth. hTERT is considered
to be an oncogene, mediating the oncogenic function of c-Myc58.
In contrast, the role of E2F2, as well as its family members, such
as E2F1, on tumorigenesis is varied from case to case, serving
either as oncogene or a tumour suppressor59. Indeed, E2F2 is
reported to suppress c-Myc-induced proliferation and
tumorigenesis60. Therefore, it appears that the E3 ubiquitin
ligase activity of ELL is particularly required for its tumour
suppressive function.
Notably, the ELL(C595A) mutant not only lost its ability to
suppress cell proliferation and xenograft tumour growth, but also
promoted metastasis, likely by gaining an invasive capability, which is
similar to that exhibited by classic tumour suppressors, such as p53
and pVHL61,62. The mechanistic studies via quantitative analysis of
global proteome in xenograft tumours revealed that some metastasis-
associated proteins, including S100A4, MARCKSL1 and BAG4 were
increased in ELL(C595A) xenograft tumours compared to the control
tumours. S100A4 is a calcium-binding protein with metastasis-
promoting function40,63,64, which can induce motility and invasion of
glioblastoma cells39, participates in epithelial–mesenchymal transition
in breast cancer, and involves in liver metastasis of colorectal
cancer65. In addition, silencing of S100A4 via siRNA or shRNA and
blocking of S100A4 via anti-S100A4 antibody can reduce metastasis
formation by blocking stroma cell invasion41–43.MARCKSL1 exhibits
anti-angiogenic effects through suppression of VEGFR-2-dependent
Akt/PDK-1/mTOR phosphorylation45. BAG4 is a negative regulator
of apoptosis, which also links to tumour aggressiveness and
metastasis47,48. Therefore, ELL(C595A) mutant might promote
tumour metastasis through inducing expression of metastasis-
associated genes, particularly for inducing S100A4, a well-deﬁned
metastasis-promoting gene. However, how and why ELL(C595A)
mutant induces expression of these genes is still unknown. To further
investigate this induction and its contribution to tumour metastasis
will give insight into the physiological function of ELL(C595A)
mutant and the underlying mechanisms, leading to new treatments
for tumour metastasis.
Methods
Cell culture and transfection. HEK293, HEK293T, HCT116 and Cos7 cells were
originally obtained from ATCC. Rat1 and HO15.19 cells (c-Myc null rat ﬁbroblast
Rat1 cells) were obtained from Dr Guoliang Qing’s lab. HEK293, HEK293T, Cos7,
Rat1 and HO15.19 cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(HyClone) and HCT116 cells were maintained in McCoy’s 5A medium (HyClone),
supplemented with 10% fetal bovine serum (FBS; Hyclone) at 37 C in a humidiﬁed
atmosphere incubator containing 5% CO2. All cell lines were veriﬁed to be free of
Mycoplasma contamination before use. VigoFect (Vigorous Biotechnology) was
used for cell transfection.
Antibodies and reagents. The antibodies used were as follows: anti-ELL antibody
(A0668, 1:1,000 for IB analysis, ABclonal; 51044-1-AP, 1:1,000 for IB analysis,
Proteintech; HPA046076, 1:200 for IHC staining, Sigma-Aldrich), anti-c-Myc
antibody (9E10, 1:1,000 for IB analysis, 1:200 for IHC staining, Santa Cruz; A0309,
1:100 for endogenous IP analysis, ABclonal; D84C12, 1:1,000 for IB analysis, Cell
Signaling), anti-Flag antibody (F1804, 1:1,000 for IB analysis, Sigma); anti-HA
antibody (1:5,000 for IB analysis, Covance), anti-His antibody (H15, 1:1,000 for IB
analysis, Santa Cruz), anti-GAPDH antibody (SC-47724, 1:1,000 for IB analysis,
Santa Cruz), anti-S100A4 (ab27957, 1:1,000 for IB analysis, Abcam) and anti-a-
tubulin antibody (EPR1333, 1:10,000 for IB analysis, Epitomics). The reagents used
were as follows: chloroquine diphosphate (BioVison), AICAR (Cayman), MG132
(Calbiochem), cycloheximide (Sigma-Aldrich).
Plasmid constructs and mutants. The original wild-type c-Myc and its domain
constructs were kindly provided by Stephen Hann. HA-tagged c-Myc (P57S) and
c-Myc (T58A) were kindly provided by Scott Lowe. The original ELL andMLL-ELL
constructs were kindly provided by Ali Shilatifard. The hTERT promoter luciferase
reporter was kindly provided by Tae Kook Kim. The GFP-BM5 construct was
kindly provided by Masayuki Komada.
The domain constructs of ELL, His-ELL, Flag-ELL, pcDNA-ELL and GFP-ELL
have been described previously15. pSuper-ELL-shRNA-1 and pSuper-ELL-shRNA-
2 were constructed in the pSuper vector using the following targeting sequences:
50-CAACACCAACTACAGCCAGGA-30 (ELL-shRNA-1) and 50-GCGAGTACCT
GCACAGCAA-30(ELL-shRNA-2). His-ubiquitin and His-ubiquitin (K48R) have
been described previously66. The ELL(C595A) mutant was generated by PCR. The
human c-Myc mutants, including S62A, S62E, K51/52R, K126R, K144/149R,
K158R, K206R, K269R, K275R, K289R, K298R, K317/323R, K323R, K326R,
K342R, K355R, K371R, K389R, K392R, K397R, K398R, K412R, K422R, K428R,
K430R and 4K/R(K51/51/397/430R), were generated by PCR and cloned into the
pCGN-HAM vector (kindly provided by William Tansey). The E2F2 promoter
luciferase reporter (E2F2-luc.) was generated by PCR and cloned into pGL3-Basic
(Promega). PM-c-Myc was generated by PCR and cloned into PM vector (which
contains GAL4-binding domain; Clontech).
The human E2 ubiquitin-conjugating enzyme expression plasmids, including
UbcH1, UbcH2, UbcH3, UbcH5a, UbcH5b, UbcH5c, UbcH6, UbcH7, UbcH8,
UbcH10 and Ubc13, were generated by PCR using the indicated primers
(Supplementary Table 1), and cloned into CMV-Myc vector (Clontech).
Co-immunoprecipitation and western blot analysis. Anti-c-Myc antibody, anti-
HA antibody and anti-Flag antibody-conjugated agarose beads were purchased
from Sigma-Aldrich. Protein A/G Sepharose beads were purchased from GE
Company. GST-Bind Resin was purchased from Novogen. For western blot ana-
lysis and co-immunoprecipitation of overexpressed proteins, the experimental
procedures have been described67. Because overexpression of ELL caused c-Myc
protein degradation, thus, we transfected 2–3 times more c-Myc expression plasmid
(HA-c-Myc) when co-transfecting with ELL expression vector compared with co-
transfection with c-Myc expression vector and the empty vector control. For
endogenous co-immunoprecipitation, the experimental procedures have been
described previously15. For GST pull-down assays, GST-tagged c-Myc and His-
tagged ELL were expressed in E. coli (BL21) and puriﬁed. After co-
immunoprecipitation using GST-Bind Resin, the protein was separated by SDS–
polyacrylamide gel electrophoresis. The gel was stained with Coomassie blue or
transferred to a polyvinylidene diﬂuoride membrane for detecting His-ELL by
western blot analysis. The Fuji Film LAS4000 mini luminescent image analyzer was
used for photographing the blots. Multi Gauge V3.0 was used for quantifying the
protein levels based on the band density obtained in western blot analysis. The full-
size images are shown in Supplementary Fig. 17.
In vitro and in vivo ubiquitination assays. In vitro ubiquitination was performed
according to the protocol provided by the Ubiquitination Kit (UW9920, BioMol)
with some modiﬁcations. Brieﬂy, His6-c-Myc, His6-ELL and His6-ELL(C595A)
were expressed in E. coli and puriﬁed by Ni2þ -NTA resin (Novagen). The assays
were carried out at 37 C in a 50-ml reaction mixture containing 20Uml 1 of
inorganic pyrophophatase (Sigma-Aldrich), 5mM dithiothreitol, 5mM Mg-ATP,
100 nM E1, 2.5 mM indicated E2, 0.75–1mM E3 (1mM His-ELL or 0.75mM His-
ELL(C595A)), 1 mM target protein (His6-c-Myc) and 2.5 mM biotin-labelled ubi-
quitin. After incubated for 30–60min, the reactions were quenched by addition of
50 ml of 2 non-reducing gel-loading buffer and separated using 12% SDS–
polyacrylamide gel electrophoresis. To get accurate results, the PAGE gel was run
for a relatively longer time until protein bands smaller than 40 kDa ran out of the
bottom line of the gel as judged by the protein molecular weight marker. Then the
protein was transferred to a polyvinylidene diﬂuoride membrane. To reduce the
background, anti-c-Myc antibody (A0309, 1:1,000, ABclonal) was used for
detecting poly-ubiquitination of c-Myc via western blot analysis instead of using
HRP-Streptavidin detection system recommended by the kit for detecting bioti-
nylated-ubiquitin.
For in vivo ubiquitination assays, HEK293T cells were co-transfected with HA-
c-Myc, Myc-ELL, Myc-ELL(C595A), His-ubiquitin or His-ubiquitin (K48R).
Ubiquitination assays with His-ubiquitin or His-ubiquitin (K48R) were performed
by afﬁnity puriﬁcation on Ni2þ -NTA resin (Novagen). An anti-HA antibody was
used for detecting c-Myc poly-ubiquitination.
Lentivirus-mediated gene overexpression and knockdown. ELL, ELL(C595A),
c-Myc and c-Myc (4K/R) were subcloned into the lentivirus vector pHAGE-CMV-
MCS-IZsGreen. c-Myc short hairpin RNA (shRNA) was cloned into the lentivirus
vector LentiLox3.7 with the following targeting sequence: 50-GCCA-
TAATGTAAACTGCCT-30 (which targets 50 untranslated region of human c-Myc).
ELL short hairpin RNA was cloned into the lentivirus vector pLKO.1 vector with
the following targeting sequence: 50-CAACACCAACTACAGCCAGGA-30.
Lentiviruses for gene overexpression were generated by transfecting HEK293T
cells with a transducing vector, and the packaging vectors, psPAX2 and pMD2.G.
Lentiviruses for c-Myc knockdown or scrambled control were generated by
transfecting HEK293T cells with a transducing vector or a control vector, and the
packaging vectors, VSVG, pRSV-Rev and pMDLg/pRRE. Lentiviruses for ELL
knockdown or scrambled control were generated by transfecting HEK293T cells
with a transducing vector or a control vector, and the packaging vectors, psPAX2
and pMD2.G.
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After transfection for 8 h, the medium was replaced with fresh Dulbecco’s
modiﬁed Eagle’s medium with 10% FBS. After 40 h, virus particles in the medium
were collected, ﬁltered and transduced into target cells. Polybrene (8 mgml 1) was
added to the medium to improve infection efﬁciency.
Luciferase reporter assays. Cells were seeded in 24-well plates and transfected
with the indicated luciferase reporters using VigoFect (Vigorous Biotechnology).
pTK-Renilla was used as an internal control. For mammalian one-hybridization
assays, the pRF-luciferase construct (Stratagene) was used as reporter. Luciferase
activity was measured 20–24 h after transfection using the Dual-luciferase Reporter
Assay System (Promega).
Semi-quantitative RT–PCR. Total RNA was extracted from cells using the Trizol
reagent (Invitrogen), and cDNA was synthesized using a ﬁrst strand cDNA
synthesis kit (Fermentas). The following primers were used for RT–PCR analysis:
human c-Myc, sense: 50-TTCTGTGGAAAAGAGGCAGG-30 and antisense:
50-TGCGTAGTTGTGCTGATGTG-30 ; human TERT, sense: 50-CGGAA-
GAGTGTCTGGAGCAA-30 and antisense: 50-GGATGAAGCGGAGTCTGGA-30;
human E2F2, sense: 50-GGCCAAGAACAACATCCAGT-30 and antisense:
50-TGTCCTCAGTCAGGTGCTTG-30 . The 18 s RNA was used as an internal
control: sense: 50-TCAACTTCGATGGTAGTCGCCGT-30 and antisense:
50-TCCTTGGATGTGGTAGCCGTTCT-30.
Nucleus and nucleolus localization assays. Cos7, HEK293T and HCT116 and
Cos7 cells were co-transfected with the indicated plasmids respectively. The plas-
mids include GFP-tagged BM5 (GFP-BM5), RFP-tagged c-Myc (RFP-c-Myc),
GFP-tagged ELL (GFP-ELL), RFP-tagged Max (RFP-Max), RFP-tagged Mxd (RFP-
Mxd), HA empty vector, HA-ELL and HA-c-Myc. After transfected for 16–24 h,
the cells were examined under a ﬂuorescence microscope (Nikon) or a co-focal
microscope (Zeiss).
ChIP assays. The ChIP assays were performed according to the protocol described
previously15 with modiﬁcation. Brieﬂy, HCT116 cells with indicated transfections
for ELL overexpression or knockdown were ﬁxed in 1% formaldehyde and then
lysed in SDS buffer. Lysates were sonicated yielding DNA fragments with an
average size of 200–1,000 bp and precleared with protein A/G agarose beads. Then
lysates were immunoprecipitated by 5 mg of anti-c-Myc antibody (A0309,
ABclonal), or normal rabbit immunoglobulin-G. Antibody-nucleoprotein complex
mixtures were incubated overnight and recovered by incubation with 20 ml of
protein A/G agarose beads. After incubation, the protein A/G beads were washed
and eluted. The eluted solutions were used for detecting the promoter region of
hTERT or E2F2 by semi-quantitative RT–PCR assays. The DNA level detected in
the sample with immunoprecipitation by anti-c-Myc antibody was normalized to
the sample with immunoprecipitation by rabbit immunoglobulin-G control. The
primers speciﬁc for the hTERT promoter region are 50-TCCCCTTCAGTCCGGC
ATT-30(forward) and 50-AGCGGAGAGAGGTCGAATCG-30(reverse). The
primers speciﬁc for the E2F2 promoter region are 50-AAGTCGGTGCAGTCGAG
ACC-30(forward) and 50-GAGATCGCCGCTTGGAGATCG-30(reverse).
In vitro cell growth assays. After HCT 116 cells were stably transfected with ELL,
ELL(C595A), empty vector control, ELL-shRNA or scrambled control via lentivirus
infection, they were seeded in six-well plates at 1 105 cells per well and counted at
days 1, 2, 3 and 4 using an automatic cell counter (TC10; Bio-Rad).
Similarly, Rat1 and HO15.19 cells were stably transfected with ELL, or empty
vector control via lentivirus infection, they were seeded in six-well plates at 1 105
cells per well and counted at days 1, 2, 3 and 4 using an automatic cell counter
(TC10; Bio-Rad).
Colony formation assays. The stable-transfected HCT116 cells were seeded in
six-well plates at 2 104 cells per well (for ELL overexpression) or 1.5 104 cells
per well (for ELL knockdown). After 6 days, the colonies were ﬁxed using methanol
and stained with crystal violet (0.5% in methanol). The colony numbers were
counted based on the images obtained by a stereo microscope. Colonies of a
suitable size were counted and the numbers counted from the same area were used
for comparison.
Cell invasion assays. Transwell plates were purchased from Corning (Costar
3422). Cell invasion assays were performed following the protocol provided by the
manufacturer. Brieﬂy, HCT116 cells with different lentivirus infections were sus-
pended in serum-free McCoy’s 5A medium and put into the top wells at 5 105
cells per well; McCoy’s 5A medium supplemented with 10% FBS was added into
the bottom wells. After cultured for 36 h in a humidiﬁed atmosphere incubator
containing 5% CO2, the wells were taken out, then ﬁxed and stained by Giemsa.
The pictures were taken under a Leica stereo microscope and the colony numbers
were counted by ImageJ software.
Immunohistochemical analysis. Colon cancer tissue arrays were obtained from
Shanghai Zuocheng Bio. Co., Ltd (cat. no. HCol-Ade180Sur-04). Immunohisto-
chemical staining was also provided by the company. This array contained 180
tissues, including 90 colon cancer specimens and 90 normal colon tissues isolated
from patients with colon cancer. For comparison, two sequential arrays were
obtained for the immunohistochemical staining of c-Myc and ELL using a
monoclonal antibody against c-Myc (9E10, 1:500 for IHC staining, Santa Cruz) and
a polyclonal antibody against ELL (HPA046076, 1:500 for IHC staining, Sigma-
Aldrich). After staining, four normal colon tissues were lost in the array, so only 86
normal colon tissues were counted for further data analysis. Immunostaining was
evaluated manually and graded using a two-score system based on intensity score
and proportion score described previously68. Samples with an intensity score41.5
and a proportion score 450% were considered to have positive staining.
In vivo tumour growth in xenograft models. Animal studies were approved by
the Animal Care and Use Committee of Institute of Hydrobiology, Chinese
Academy of Sciences. HCT116 cells were infected with lentivirus encoding ELL,
ELL(C595A) or empty vector control. For the ﬁrst experiment, 15 male nude mice
(3–4 weeks of age) were randomly separated into three groups (n¼ 5 per group)
and each mouse was injected subcutaneously in the ﬂank region with 2 106
infected HCT116 cells. Three groups were injected with the three different cell
lines, including pHAGE-ELL, pHAGE-ELL(C595A) and pHAGE control, respec-
tively. For the second experiment, 15 male nude mice (4–5 weeks of age) were also
randomly separated into three groups (n¼ 5 per group) and each mouse was
injected subcutaneously in the ﬂank region with 2.2 106 parental or infected
HCT116 cells. Three groups were injected with the three different cell lines,
including parental HCT116 cells, pHAGE control and pHAGE-ELL(C595A),
respectively. The tumour volume was measured weekly starting at week 3 using the
following formula: V¼ p.abc/6 (ref. 69). After 6 weeks, the mice were killed and the
tumours were harvested to determine their weight and for gene expression analysis.
For detecting metastasis, the lungs were also harvested and histological analysis was
carried out after hematoxylin and eosin staining. All animal protocols were
approved by the Institutional Animal Care and Use Committee of Institute of
Hydrobiology, Chinese Academy of Sciences.
Quantitative analysis of global proteome in xenograft tumours. Ten male nude
mice (4–5 weeks of age) were randomly separated into two groups (n¼ 5 per
group) and each mouse was injected subcutaneously in the ﬂank region with
2.2 106 HCT116 cells infected with pHAGE control or pHAGE-ELL(C595A).
After 3 weeks, the mice were killed, the tumours were harvested, and three pHAGE
control tumours and three pHAGE-ELL(C595A) tumours were sent to PTM-
Biolabs Co., Ltd (Hangzhou, China) for quantitative analysis of global proteome.
Semi-quantitative RT–PCR and western blot were employed for veriﬁcation of gene
upregulation. The primers used for semi-quantitative RT–PCR are listed in
Supplementary Table 2.
Statistical analysis. Luciferase, semi-quantitative RT–PCR, in vitro cell growth,
colony formation and cell invasion assay data are reported as mean ±s.e.m. of
three independent experiments performed in triplicate. For the in vivo studies, data
are reported as mean ±s.e.m. The statistical analysis was performed using
GraphPad Prism 5 (unpaired t-test) (GraphPad Software Inc.).
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